Treat to Target: Raising the Bar to Control Moderate to Severe Plaque Psoriasis With Interleukin Inhibition
1.25 / AMA PRA Category 1 CreditsTM
Provided by Haymarket Medical Education
Supported by an educational grant from Novartis Pharmaceuticals Corporation
Psoriasis is a common, chronic, immune-mediated, inflammatory condition that is now considered a systemic disease with multiple comorbidities, many of which are related to cardiovascular disease.
Unfortunately, expert guidelines have not kept pace with the emergence of new treatments for the condition, and a number of gaps have been identified between best practices in the management of psoriasis and what actually transpires in routine clinical care.
In response to those shortfalls, this enduring myCME TOWN WALLTM activity convenes a group of clinical experts to discuss evidence-based perspectives on the optimal management of moderate to severe plaque psoriasis, including the implementation of a treat-to-target approach that incorporates biologics, either alone or in combination with topical agents. This unique, interactive program was designed to engage learners as active participants while improving their ability to better utilize individualized, targeted therapeutic strategies for psoriasis that also address common comorbidities.
This activity is designed for dermatologists, primary care clinicians (family medicine and internal medicine [IM] physicians, nurse practitioners [NPs], and physician assistants [PAs]), and other clinicians who care for patients with psoriasis.
Conflict Of Interest Disclosure Policies
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Peter Salgo, MD
Professor of Medicine and Anesthesiology
Columbia University College of Physicians and Surgeons
Associate Director, Surgical Intensive Care
Columbia University Medical Center
New York, NY
Dr. Salgo has no relevant financial relationships to disclose.
Joel M. Gelfand, MD, MSCE
Professor of Dermatology and Epidemiology
Vice Chair, Clinical Research
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Dr. Gelfand serves as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GSK, Janssen Biologics, Novartis, Pfizer, Inc., Regeneron, Sanofi, and UCB (data safety monitoring board). He has also received honoraria and research support (to the Trustees of the University of Pennsylvania) from AbbVie, Celgene, Janssen Biologics, Novartis, Ortho Dermatologics, Pfizer, Inc., and Sanofi, and he is a co-patent holder of resiquimod for the treatment of cutaneous T-cell lymphoma.
Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Lebwohl has received research support from AbbVie, Boehringer lngelheim, Celgene, Eli Lilly, lncyte, Janssen/Johnson & Johnson, LEO Pharma, MedImmune/AstraZeneca, Novartis, Pfizer, Inc., SCIderm, UCB, Valeant, and Vidac. He is also a consultant for Allergan, Aqua Pharmaceuticals, Boehringer lngelheim, LEO Pharma, Menlo Therapeutics, Mitsubishi Tanabe Pharma America, Promius Pharma, and Theravance Biopharma.
Neil J. Korman, MD, PhD
Professor of Dermatology
University Hospitals Cleveland Medical Center
Dr. Korman serves as a consultant for Novartis and is an advisory board member for AbbVie, Celgene, Eli Lilly, Genentech, GSK, Immune Pharmaceuticals, Janssen, Principia Biopharma, Regeneron, Sun Pharmaceuticals, and Valeant. He also receives research support as an investigator for Celgene, Dermira, Eli Lilly, LEO Pharma, Merck & Co., Inc., Pfizer, Inc., Prothena, Regeneron, Rhizen Pharmaceuticals S.A., and UCB and has received honoraria as a speaker for AbbVie, Eli Lilly, Janssen, and Novartis.
Jashin J. Wu, MD
Medical Board Member
National Psoriasis Foundation
Councilor, International Psoriasis Council
St. Louis, MO
Dr. Wu serves as a consultant for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Sun Pharmaceutical, and UCB. He also serves on the speakers’ bureaus for Celgene, Novartis, Sun Pharma, and UCB and receives research support from AbbVie, Amgen, Eli Lilly, Janssen, and Novartis.
Wendy Cantrell, DNP, CRNP
UAB School of Medicine
Department of Dermatology
Ms. Cantrell serves as a consultant for Eli Lilly, Janssen, and Novartis and serves on the speakers’ bureaus for Eli Lilly, Janssen, LEO Pharma, Novartis, and Sun Pharmaceutical.
Scott Freeman MS, PA-C
St. Petersburg, FL
Mr. Freeman has no relevant financial relationships to disclose.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
Additional Credit Information
Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 Category 1 Credits for completing this activity.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Astellas Pharma US, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.